Skip to main content

Weightmans advises 3D Bio-Tissues on six figure funding

A corporate team from national law firm Weightmans has advised 3D Bio-Tissues, creators of an innovative tissue engineering technology, on its…

A corporate team from national law firm Weightmans has advised 3D Bio-Tissues, creators of an innovative tissue engineering technology, on its second round of funding of £420,000 to accelerate development of its tissue engineered products to market.

3D Bio-Tissues has identified a significant and unique commercial opportunity in the rapidly developing 3D tissue technology area, where it aims to offer superior tissue replicates for the clinical and food markets. For clinical indications, these engineered tissue replicates will uniquely conform to the hosts’ needs in terms of shape and nano-structure, providing regenerative cells and materials for the restoration of the patients’ skin or cornea. For food products, its technology allows the creation of highly-structured tissues, produced in animal-free conditions for the rapidly expanding lab-based meat industry.

3D Bio-Tissues CEO, and co-founder Dr Che Connon, commented

“We are delighted with the success of this funding round. I’m particularly pleased that our existing investors chose to reinvest in this round. We are receiving a lot of interest and excitement for our products and the novel technology underpinning the production of our 3D bio-tissues. This latest investment will allow us to grow the business faster and reach new markets.”

Partner Paul Wigham and Principal Associate Kirsty Adamson from Weightmans advised 3D Bio-Tissues on the investment. Paul commented:

“At Weightmans we pride ourselves on our innovation – working in new ways and with creative organisations whose work is grounded in the latest science and technology. The work of 3D Bio-Tissues is truly ground-breaking, and we were delighted to support the business on securing this new round of investment, which will pave the way for further cutting-edge advances in this field.”

 

 

Share on Twitter